EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Hypoxia-driven immune resistance to anti-PD-1/PD-L1 therapy: Mechanistic insights and therapeutic opportunities

Kaining Gao, Yunong Li, Xueyi Song, Mingyi Ju, Wei Liu, Jiabin Xu, Lili Jie, Hongye Zhang, Qian Wei, Lin Zhao

Pharmacological Research · 2026-08 · 230 · 108307

DOI: 10.1016/j.phrs.2026.108307 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2026-08. Verfasst von Kaining Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China. Hauptthemen laut MEDLINE: Neoplasms, Programmed Cell Death 1 Receptor, B7-H1 Antigen, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China-Liaoning Joint Fund, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade targeting programmed death protein-1 (PD-1) and its ligand PD-L1 has shown substantial therapeutic benefit in only a subset of patients with solid tumors, highlighting the urgent need to improve cancer immunotherapy outcomes. Hypoxia, a hallmark of the tumor microenvironment (TME), plays a critical role in modulating antitumor immunity and contributes to resistance against PD-1/PD-L1 blockade. Hypoxia influences multiple microenvironmental factors, affecting disease progression, treatment responses, and prognosis in solid tumors. As a result, hypoxia has emerged as a pivotal therapeutic target in combination immunotherapy approaches. This review explores the molecular and cellular mechanisms by which the hypoxic TME induces resistance to PD-1/PD-L1 blockade across distinct tumor types. Furthermore, we examine current strategies that target hypoxia to enhance immunotherapy efficacy and discuss the potential benefits of combination regimens. Collectively, this study provides a comprehensive framework for the rational design and clinical optimization of PD-1/PD-L1 inhibitors, with the goal of expanding their therapeutic applicability in solid malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsProgrammed Cell Death 1 ReceptorB7-H1 AntigenDrug Resistance, NeoplasmImmune Checkpoint InhibitorsHumansAnimalsTumor MicroenvironmentImmunotherapy

Stichwörter der Autor:innen

HypoxiaImmunotherapyPD-1/PD-L1 inhibitorsResistanceTumor microenvironment

Substanzen

Programmed Cell Death 1 ReceptorB7-H1 AntigenImmune Checkpoint InhibitorsCD274 protein, humanPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China.
  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China; School of Pharmacy, Shenyang Medical College, China.
  • Department of China Medical University Durg and Food Test Center, School of Pharmacy, China Medical University, Puhe Road No.77, Shenyang, Liaoning 110122, China. Electronic address: zhanghongye52@163.com.
  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China. Electronic address: qwei@cmu.edu.cn.
  • Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang 110122, China; Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Sheny…

Förderung

  • National Natural Science Foundation of China-Liaoning Joint Fund
  • National Natural Science Foundation of China

Zitieren

APA

Gao, K., Li, Y., Song, X., Ju, M., Liu, W., Xu, J., Jie, L., Zhang, H., Wei, Q., & Zhao, L. (2026). Hypoxia-driven immune resistance to anti-PD-1/PD-L1 therapy: Mechanistic insights and therapeutic opportunities. Pharmacological Research, 230, 108307. https://doi.org/10.1016/j.phrs.2026.108307

Vancouver

Gao K, Li Y, Song X, Ju M, Liu W, Xu J, et al. Hypoxia-driven immune resistance to anti-PD-1/PD-L1 therapy: Mechanistic insights and therapeutic opportunities. Pharmacological Research. 2026;230:108307. doi:10.1016/j.phrs.2026.108307

BibTeX
@article{Gao2026,
  author = {Gao, Kaining and Li, Yunong and Song, Xueyi and Ju, Mingyi and Liu, Wei and Xu, Jiabin and Jie, Lili and Zhang, Hongye and Wei, Qian and Zhao, Lin},
  title = {Hypoxia-driven immune resistance to anti-PD-1/PD-L1 therapy: Mechanistic insights and therapeutic opportunities},
  journal = {Pharmacological Research},
  year = {2026},
  volume = {230},
  pages = {108307},
  doi = {10.1016/j.phrs.2026.108307}
}
Kostenlos starten →